Table 5.
Associations of H19 long noncoding RNA polymorphisms and specific molecular subtypes for breast cancer patients
| rs217727
|
rs2839698
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Cases (CC/CT + TT) |
P-valuea | OR (95% CI)b | P-valuec | Cases (CC/CT + TT) |
P-valuea | OR (95% CI)b | P-valuec | |
| ER status | ||||||||
| Positive | 268/410 | 0.004* | 1.34 (1.09–1.64) | 0.577 | 291/387 | 0.134 | 1.17 (0.95–1.43) | 0.111 |
| Negative | 135/192 | 0.135 | 1.22 (0.94–1.58) | 161/166 | 0.418 | 0.9 (0.7–1.16) | ||
| PR status | ||||||||
| Positive | 247/371 | 0.006 | 1.34 (1.08–1.66) | 0.675 | 259/359 | 0.075 | 1.21 (0.98–1.49) | 0.088 |
| Negative | 156/231 | 0.072 | 1.25 (0.98–1.59) | 193/194 | 0.313 | 0.88 (0.7–1.12) | ||
| HER2 status | ||||||||
| Positive | 118/157 | 0.651 | 1.07 (0.81–1.41) | 0.71 | 138/137 | 0.364 | 0.88 (0.67–1.16) | 0.126 |
| Negative | 285/445 | 0.001* | 1.40 (1.14–1.71) | 313/416 | 0.186 | 1.14 (0.94–1.39) | ||
| HR+ HER2− | 208/336 | 0.001* | 1.45 (1.16–1.81) | 231/313 | 0.169 | 1.16 (0.94–1.45) | ||
| TNBC | 68/100 | 0.198 | 1.25 (0.89–1.75) | 77/91 | 0.759 | 1.05 (0.75–1.47) | ||
Notes:
a
P<0.005,
*
significant after Bonferroni correction;
b
adjusted by age, body-mass index, age at menarche and menopause, menopausal status, number of pregnancies, and family history of breast cancer;
c
for heterogeneity test.
Abbreviations: CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; OR, odds ratio; PR, progesterone receptor; TNBC, triple-negative breast cancer.